Telix Reports Third Quarter 2026 Financial Performance

Pixclara's first commercial doses were administered in September, adding an approved glioma imaging product to Telix's portfolio.

Rhea-AI Summary

Telix Pharmaceuticals (TLX) reported third-quarter 2026 revenue of US$245 million, up 19% from the same quarter a year earlier. Precision Medicine revenue rose 30% year over year to US$201 million, while manufacturing revenue fell 6% to US$44 million. Group revenue declined 1% from Q2.

Telix expects FY 2026 revenue and other income above US$1 billion, with revenue tracking toward the upper end of US$950 million–US$970 million, plus US$40 million of other income. Revised research and development spending guidance is US$240 million–US$260 million, previously US$230 million–US$270 million.

The FDA approved Pixclara for glioma imaging, and BiPASS completed enrollment. The announced ITM merger carries US$1.65 billion upfront consideration and up to US$700 million contingent consideration, subject to shareholder approval. Zircaix resubmission remains planned following a Complete Response Letter.

20 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

2 major · 9 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointIPAX-2 met its primary endpoint, establishing a maximum tolerated dose of two 5 GBq cycles with standard care.
• Moderate pointGroup revenue of US$245 million rose 19% year over year in Q3 2026, but fell 1% sequentially.
• Moderate point. Forward-looking: it has not happened yet and may not happen.FY 2026 revenue and other income are expected above US$1 billion; revenue tracks toward guidance's upper end.
• Moderate pointPixclara received FDA approval for glioma imaging; first commercial doses were administered in September 2026.
• Moderate point. Forward-looking: it has not happened yet and may not happen.ITM merger would add a late-stage therapeutic portfolio and isotope production capabilities to Telix.

15 minor points

• Minor pointPrecision Medicine revenue of US$201 million rose 30% year over year; reported sequential change was —%.
• Minor pointU.S. dose volumes increased 1% quarter over quarter for Gozellix and Illuccix.
• Minor point. Forward-looking: it has not happened yet and may not happen.Precision Medicine revenue growth above 25% in 2026 remains Telix's expectation.
• Minor pointBiPASS Phase 3 completed enrollment of 350 patients for pre-biopsy prostate cancer diagnosis.
• Minor pointBiPASS received Fast Track Designation and FDA support for a new drug application pathway.
• Minor pointProstACT Global Part 2 continues enrollment in seven countries; regulatory approvals also obtained in China and Japan.
• Minor point. Forward-looking: it has not happened yet and may not happen.OPTIMAL-PSMA completed enrollment of 120 patients; a data readout is expected in the first half of 2027.
• Minor pointOPTIMAL-e Phase 2 continues enrolling patients for evaluation of TLX597-Tx.
• Minor pointLUTEON pivotal trial continues enrolling patients to evaluate TLX250-Tx in advanced clear cell kidney cancer.
• Minor pointIPAX BrIGHT completed first-cohort enrollment; an FDA amendment was filed to support U.S. Part 1b expansion.
• Minor pointIPAX-2 observed no dose-limiting toxicities, supporting advancement to Phase 2.
• Minor pointIlluccix Japan Phase 3 completed enrollment; Telix is preparing a new drug application.
• Minor pointPixclara label expansion study is advancing in Phase 3 following FDA clearance of the investigational application.
• Minor pointARTMS secured contracts for 50 QUANTM Irradiation Systems globally.
• Minor pointEkalia collaboration secures long-term, priority astatine-211 isotope access for Telix's alpha therapy pipeline.

Negative

• Major pointITM upfront consideration is US$1.65 billion on a cash-free, debt-free basis. 45% of market cap
• Major point. Forward-looking: it has not happened yet and may not happen.Approximately US$1.25 billion in Telix shares is expected for ITM shareholders as ADRs, diluting existing holders. 34% of market cap
• Moderate pointZircaix resubmission remains pending as Telix addresses remaining third-party manufacturing observations following a corrected Complete Response Letter.
• Minor point. Forward-looking: it has not happened yet and may not happen.Up to US$700 million contingent consideration may become payable upon ITM-11 regulatory approvals and commercial sales milestones.
• Minor pointITM transaction requires Telix shareholder approval; a shareholder meeting is expected December 1, 2026 (AEDT).

4 minor points

• Minor pointManufacturing revenue of US$44 million declined 6% year over year and 2% sequentially in Q3 2026.
• Minor pointProstACT Global U.S. Part 2 progression awaits the investigational application amendment Telix is finalizing.
• Minor pointPixlumi's European marketing application remains under review.
• Minor pointIlluccix conditional approval in Japan remains under review by the medicines regulator.

News Explained

Under the announced ITM merger, which remains subject to Telix shareholder approval and customary closing conditions, ITM shareholders are expected to receive about US$1.25 billion in Telix shares released as ADRs, making them owners alongside existing holders if the deal closes. The company expects a shareholder meeting on December 1, 2026.

Key Figures

Group revenue: US$245 million; increased 19% Precision Medicine revenue: US$201 million; increased 30% TMS revenue: US$44 million; decreased 6% +5 more

Group revenue

US$245 million; increased 19%

Q3 2026 versus Q3 2025; in line with expectations

Precision Medicine revenue

US$201 million; increased 30%

Q3 2026 versus Q3 2025

TMS revenue

US$44 million; decreased 6%

Q3 2026 versus Q3 2025

FY 2026 revenue guidance

US$950 million to US$970 million

Revenue guidance; tracking toward the upper end

Other income guidance

US$40 million

FY 2026; included in the stated revenue and other income outlook

R&D expenditure guidance

US$240 million to US$260 million

FY 2026; revised from US$230 million to US$270 million

Merger upfront consideration

US$1.65 billion

ITM transaction; cash-free, debt-free basis

Contingent merger consideration

Up to US$700 million

Payable upon specified ITM-11 regulatory approvals and commercial sales milestones

Historical Context

1 past event · Latest: Sep 20

1 event

1. Sep 20

   Merger agreement

   24h Move

   -10.2%

   Agreement set US$1.65B upfront consideration and up to US$700M contingent on milestones.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

psma-pet, nda, fast track designation, maximum tolerated dose, +1 more

5 terms

psma-pet medical

"Telix's commercial PSMA-PET imaging portfolio continued to strengthen its market position"

A PSMA-PET scan is a medical imaging test that uses a tiny radioactive tracer that sticks to a protein commonly found on prostate cancer cells, allowing a PET scanner to highlight tumors and metastases like a GPS map for cancer. It matters to investors because it can change how accurately disease is detected and staged, influence treatment choices, and drive demand, reimbursement and sales for imaging agents, scanners and related services.

nda regulatory

"the FDA supporting an NDA pathway"

An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.

fast track designation regulatory

"granting Fast Track Designation"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

maximum tolerated dose medical

"establishing a maximum tolerated dose (MTD)"

Maximum tolerated dose is the highest amount of a substance, such as a medication or chemical, that can be used without causing unacceptable side effects or harm. It’s like finding the maximum speed you can drive without risking a ticket or accident. For investors, understanding this concept helps gauge how much risk or exposure is safe or sustainable in a given situation.

complete response letter regulatory

"Following receipt of the corrected Complete Response Letter (CRL)"

A complete response letter is an official communication from a drug or medical-device regulator, such as the U.S. Food and Drug Administration (FDA), telling a company that a marketing application cannot be approved in its current form and listing the specific deficiencies to be fixed. For investors it matters because it pauses or delays a product’s path to market—like a building inspector issuing a list of repairs before a certificate of occupancy—affecting revenue timing, costs and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026).

Q3 2026 Highlights¹

• Group revenue of US$245 million increased 19% over the prior corresponding quarter (Q3 2025) driven by continued strong demand for the commercial portfolio, in line with expectations. September sales drove a higher quarterly exit rate indicating continued strength in underlying demand for Telix's PSMA products.
• Precision Medicine revenue of US$201 million, increased 30% over the prior corresponding quarter, driven by both Gozellix® and Illuccix®². Telix's commercial PSMA-PET imaging³ portfolio continued to strengthen its market position, driven by strong demand for our clinically differentiated products.
• U.S. Food and Drug Administration (FDA) approved Pixclara®⁴ for glioma imaging, marking a significant milestone and establishing the first approved imaging agent for this indication in the U.S.⁵. The first commercial doses were administered in September 2026⁶.
• BiPASS®, a Phase 3 study evaluating pre-biopsy prostate cancer detection, completed enrollment⁷, with the FDA supporting an NDA pathway and granting Fast Track Designation⁸.
• Telix announced a merger with Isotope Technologies Munich SE (ITM). The merger creates a leading radiopharmaceutical platform with one of the industry's broadest therapeutics pipelines, supported by best-in-class isotope production, manufacturing, and supply chain capabilities⁹.
• Telix reaffirmed that FY 2026 revenue and other income is expected to be in excess of US$1 billion, with revenue tracking in line with upper end of FY 2026 guidance of US$950 million to US$970 million plus US$40 million of other income. The Company has also revised its FY 2026 R&D expenditure guidance range to US$240 million to US$260 million.
  
  

Q3 2026 Revenue

Revenue (US$M)	Q3 2026	Q3 2025	% Change	Q2 2026	% Change
Group revenue	245	206	19%	247	(1)%
Precision Medicine revenue10	201	155	30%	202	—%
TMS revenue11	44	47	(6)%	45	(2)%

Executive Commentary

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, "Demand for both Gozellix and Illuccix remained strong during the quarter, with U.S. dose volumes increasing 1% quarter-over-quarter, in line with our expectations and reflecting expected summer seasonality. We are pleased by the strong September exit run rate, supporting our confidence in delivering over 25% Precision Medicine revenue growth in 2026. We achieved an important milestone with the FDA approval of Pixclara, expanding our commercial portfolio, establishing a presence in neuro-oncology and further diversifying our revenue base. During the quarter, we announced a transformative merger with ITM, creating a leading vertically integrated radiopharmaceutical company with one of the industry's broadest therapeutic pipelines and expanded isotope production and global manufacturing capabilities. This is aligned with our long-term growth strategy reinforcing our ability to reliably serve patients at scale."

Therapeutics Business Unit

• TLX591-Tx (¹⁷⁷Lu rosopatamab tetraxetan): Following FDA review and alignment of the Part 1 safety data, Telix is finalizing its IND amendment to the FDA to support progression to Part 2 of the ProstACT Global Phase 3 study in the U.S.¹². Outside the U.S., Part 2 of the global study continues to enroll patients across seven countries: Australia, New Zealand, Canada, Türkiye, the UK, Singapore, and South Korea. Regulatory approvals have also been obtained to proceed in China and Japan¹³.
• TLX597-Tx (¹⁷⁷Lu-DOTA-HYNIC-panPSMA): OPTIMAL-PSMA¹⁴, a Phase 2 study evaluating TLX597-Tx in metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer¹⁵, completed enrollment of 120 patients¹⁶. A data readout is expected in the first half of 2027. OPTIMAL-e¹⁷, a Phase 2 study evaluating TLX597-Tx in metastatic androgen pathway modulator-naive or -sensitive (mAPMN/S) prostate cancer¹⁸, continues to demonstrate strong enrollment momentum.
• TLX250-Tx (¹⁷⁷Lu girentuximab tetraxetan): Continued enrollment of patients in LUTEON¹⁹, a pivotal trial of TLX250-Tx in advanced clear cell Renal Cell Carcinoma (ccRCC). The trial is evaluating the safety and efficacy of TLX250-Tx compared with the investigator’s choice of monotherapy consistent with standard of care.

• TLX101-Tx (iodofalan ¹³¹I): Following full enrollment of the first cohort in Part 1 of the Phase 3 IPAX BrIGHT study²⁰, an IND amendment was filed with the FDA to support expansion of the trial into Part 1b in the U.S. IPAX-2²¹, a Phase 1 study of TLX101-Tx in patients with newly diagnosed glioblastoma met its primary endpoint, establishing a maximum tolerated dose (MTD) of two 5 GBq cycles in combination with standard of care. No dose-limiting toxicities were observed, supporting advancement of IPAX-2 to Phase 2²².
  
  

Precision Medicine Business Unit

⁶⁸Ga-PSMA-11 for prostate cancer imaging:

• BiPASS®, a Phase 3 study of ⁶⁸Ga-PSMA-11 PET in combination with MRI for the diagnosis of prostate cancer in the pre-biopsy setting, completed enrollment of 350 patients. Rapid enrollment underscores the unmet need for a minimally invasive option for prostate cancer diagnosis. The study builds on the clinical foundation established by the PRIMARY²³ and PRIMARY2²⁴ studies and is intended to support regulatory submissions. The FDA has supported an NDA pathway that could facilitate reimbursement and granted Fast Track Designation, which may enable an expedited review.
• With enrollment complete in the Phase 3 registrational study of TLX591-Px (Illuccix) in Japan²⁵, Telix is preparing for NDA submission and potential market entry. A Conditional Approval is currently under review by Japan's Pharmaceutical and Medical Devices Agency (PMDA) and is expected to facilitate an expedited review process.
  
  

TLX101-Px (floretyrosine F 18) for brain cancer imaging:

• Telix's Marketing Authorization Application (MAA) for Pixlumi®²⁶ in Europe remains under review.
• Following the FDA clearance of the IND application, Telix is advancing a Phase 3 registrational study to support expansion of the Pixclara label for the diagnosis of brain metastases.
  
  

TLX250-Px, Zircaix®²⁷ (⁸⁹Zr-girentuximab senvedoxam) for kidney cancer imaging:

• Following receipt of the corrected Complete Response Letter (CRL), Telix is finalizing its Biologics License Application (BLA) resubmission package, addressing the remaining third-party manufacturing observations. Resubmission to the FDA is planned in the near term and remains a top priority for the Company in 2026.
  
  

Telix Manufacturing Solutions (TMS)

• Through RLS, Telix has established a growing network of micro-pharmacy sites, known as UroOncRx™, providing urologists with onsite access to our imaging agents, particularly in underserved and remote markets. Multiple sites are now operational and dispensing product, further strengthening our radiopharmacy infrastructure and expanding patient access.
• ARTMS, a Telix company, has secured contracts for 50 QUANTM® Irradiation Systems (QIS®) globally, achieving a key commercial milestone and reflecting continued demand for its isotope production technology.
• Telix announced a collaboration with Ekalia²⁸, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) and Framatome, to advance scalable U.S. production of astatine-211 (²¹¹At), an alpha-emitting radioisotope being investigated for targeted alpha therapy. The first IBA alpha-beam cyclotron installation at Telix’s RLS Radiopharmacies site in Trevose near Philadelphia (PA) is intended to establish a reproducible production model, with the potential for further rollout across the RLS network as demand develops. The collaboration secures long-term, priority isotope access for Telix’s alpha therapy pipeline, while also supporting third-party academic and industry programs.
  
  

Corporate Updates

• Telix announced a transformational merger with ITM, the world's leading supplier of therapeutic radioisotopes, reinforcing its long-term strategy as a vertically integrated radiopharmaceutical company and further strengthening one of the industry's broadest therapeutic pipelines. ITM brings a complementary late-stage portfolio led by ITM-11 (¹⁷⁷Lu-edotreotide) for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), as well as industry-leading isotope capabilities anchored by the only globally scaled commercial-grade ¹⁷⁷Lu production platform. The transaction includes upfront consideration of US$1.65 billion on a cash-free, debt-free basis, with ITM shareholders expected to receive approximately US$1.25 billion in Telix shares released as ADRs. Additional contingent consideration of up to US$700 million may be paid upon achievement of future regulatory approvals and commercial sales milestones for ITM-11. The transaction remains subject to Telix shareholder approval and customary closing conditions. A General Meeting of Shareholders is expected to be held on December 1, 2026 (AEDT).
• Mr. David Gill was appointed Chair of the Board on September 1, 2026²⁹. Mr. Gill is a life sciences executive with more than 35 years of experience in biopharma, radiopharmaceuticals and medical devices. He has held senior leadership positions, including President, Chief Operating Officer and Chief Financial Officer roles at multiple public companies, and brings extensive expertise in capital markets, governance, business scaling and corporate strategy. He currently serves on the boards of several healthcare companies and holds degrees from Wake Forest University and Emory University.
• Mr. Marcin Firek will join Telix as Company Secretary, effective October 21, 2026. Mr. Firek brings extensive experience in corporate governance, legal affairs, risk management and public company administration, including for dual-listed Australian and U.S. companies. Most recently, he served as Head of Enterprise & Operational Risk at PwC Australia. Previously, he led the Company Secretary team at Woolworths Group Limited, ASX Limited and James Hardie Industries Plc. Earlier in his career, he practiced corporate and M&A law at MinterEllison. Mr. Firek will be the primary person responsible for communications with the ASX under ASX Listing Rule 12.6. Mr. Shomalin Naidoo has also ceased his appointment as interim Company Secretary effective today.
  
  

FY 2026 guidance

• Telix expects FY 2026 revenue and other income to exceed US$1 billion, with revenue tracking toward the upper end of its FY 2026 guidance of US$950 million to US$970 million, including US$40 million in other reported income.
• Revenue guidance reflects product sales in markets where marketing authorization has been granted, includes a full-year contribution from RLS, and incorporates anticipated sales of Pixclara.
• Telix revises its FY 2026 R&D expenditure guidance range to US$240 million to US$260 million, previously US$230 million to US$270 million, subject to the achievement of planned clinical, regulatory and development milestones.
  
  

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.

Telix's commercial franchise is anchored by its precision diagnostics portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S., Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. FDA, and Pixclara® (floretyrosine F 18) approved by the FDA for glioma imaging. The Company's late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (iodofalan ¹³¹I) in recurrent glioblastoma, and TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

Investor Relations Annie Kasparian Annie.kasparian@telixpharma.com Charlene Jaw Charlene.jaw@telixpharma.com

Media Eliza Schleifstein Eliza@schleifsteinpr.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.

Guidance Disclaimer

The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information, risks and assumptions.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

_____________________________________________ 1 The financial information for the quarter ended September 30, 2026 is unaudited. 2 Illuccix® (kit for the preparation of gallium-68 gozetotide injection). Gozellix® (kit for the preparation of gallium-68 gozetotide injection). 3 Imaging of prostate-specific membrane antigen with positron emission tomography. 4 Pixclara® (floretyrosine F 18). 5 Telix ASX disclosure September 14, 2026. 6 Telix press release October 6, 2026. 7 Telix ASX disclosure September 2, 2026. ClinicalTrials.gov ID: NCT07052214. 8 Telix ASX disclosure September 30, 2026. 9 Telix ASX disclosure September 21, 2026. 10 Primarily sales of Illuccix and Gozellix in our Precision Medicine business. 11 Telix Manufacturing Solutions (TMS) third-party revenue predominantly driven by RLS Radiopharmacies (RLS), excludes Illuccix and Gozellix sales and TMS inter-segment revenue. 12 Telix ASX disclosure July 2, 2026. ClinicalTrials.gov ID: NCT06520345. 13 Telix ASX disclosure December 17, 2025. 14 Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437. 15 Formerly known as metastatic castration-resistant prostate cancer (mCRPC). 16 Telix LinkedIn June 25, 2026. 17 Australian New Zealand Clinical Trials Registry ID: ACTRN12626000034336. 18 Formerly known as metastatic hormone-sensitive prostate cancer (mHSPC). 19 ClinicalTrials.gov ID: NCT07197580. 20 ClinicalTrials.gov ID: NCT07100730. 21 ClinicalTrials.gov ID: NCT05450744 22 Telix media release May 19, 2026. 23 Emmett et al. Eur Urol. 2021. 24 Buteau et al. Lancet Oncol. 2026. ClinicalTrials.gov ID: NCT05154162. 25 Telix media release July 17, 2026. 26 Brand name subject to final regulatory approval. 27 Brand name subject to final regulatory approval. 28 Telix media release October 19, 2026. 29 Telix ASX disclosure September 1, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Telix's FY 2026 financial guidance?

Telix expects FY 2026 revenue and other income to exceed US$1 billion, with revenue tracking toward the upper end of US$950 million to US$970 million, plus US$40 million of other income. Revised research and development expenditure guidance is US$240 million to US$260 million, subject to planned clinical, regulatory and development milestones.

What product sales are included in Telix's FY 2026 revenue guidance?

Telix's revenue guidance covers product sales in markets where marketing authorization has been granted. It includes a full-year contribution from RLS and anticipated Pixclara sales.

What is the next step for Telix's Zircaix FDA application?

Telix plans a near-term resubmission of its biologics license application for Zircaix. Following receipt of a corrected Complete Response Letter, the company is finalizing the package to address remaining third-party manufacturing observations.